PDL BioPharma, Inc. (NASDAQ:PDLI)

CAPS Rating: 3 out of 5

A biopharmaceutical company focused on discovering, developing and commercializing innovative therapies for severe or life-threatening illnesses.

Recs

0
Player Avatar deal4412 (< 20) Submitted: 6/17/2012 4:12:38 AM : Outperform Start Price: $6.25 PDLI Score: +22.39

Magic formula pick, shows up on multiple mechanical stock screens with proven returns over 20 plus years. Undervalued.

Featured Broker Partners


Advertisement